Tsuchisaka H, Takase M
Department of Ophthalmology, Tokyo Women's Medical College, Daini Hospital, Japan.
Ann Ophthalmol. 1990 Jan;22(1):15-9, 23.
Effects of topical flurbiprofen, a highly potent prostaglandin synthetase inhibitor, were evaluated during planned extracapsular cataract extraction in diabetic and nondiabetic patients. One drop of flurbiprofen 0.1% or vehicle solution was instilled preoperatively and three times a day postoperatively for seven days. Pupil size was measured at several stages throughout and after the operation. Further, intraocular pressure before and after the operation was compared. In the nondiabetic patients, aqueous cells and flare, cells in the vitreous body, and pericorneal injection were examined as postoperative inflammatory responses. In the nondiabetic patients pupillary constriction was significantly suppressed by flurbiprofen at the end of anterior capsulotomy (P less than .05) and at the end of surgery (P less than .01). In the vehicle group, postoperative reduction in intraocular pressure was significant compared with that of the flurbiprofen group. These effects were not found in the diabetic patients. Inflammatory responses were not suppressed in the flurbiprofen group compared with the control group except for pericorneal injection.
在糖尿病和非糖尿病患者进行计划性囊外白内障摘除术期间，评估了强效前列腺素合成酶抑制剂氟比洛芬局部用药的效果。术前滴入一滴0.1%氟比洛芬溶液或赋形剂溶液，术后每天滴三次，共七天。在手术过程中和术后的几个阶段测量瞳孔大小。此外，比较手术前后的眼压。在非糖尿病患者中，检查房水细胞和闪光、玻璃体中的细胞以及角膜周围注射情况作为术后炎症反应。在非糖尿病患者中，氟比洛芬在前囊切开术结束时（P<0.05）和手术结束时（P<0.01）显著抑制瞳孔收缩。在赋形剂组中，与氟比洛芬组相比，术后眼压降低显著。在糖尿病患者中未发现这些效果。与对照组相比，氟比洛芬组除角膜周围注射外，炎症反应未得到抑制。
